IDXG 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-12

• ● our reliance on sales of our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2, following the loss of reimbursement for and resulting discontinuance of PancraGEN®, our pancreatic cancer test;

• ● the delisting of our Common Stock from Nasdaq, the removal of our Common Stock from trading on the OTCQX on August 18, 2025 and the subsequent trading of our Common Stock on the OTCID have adversely affected and may continue to adversely affect our Common Stock and business and financial condition…

• ● the potential impact of future contingent liabilities on our financial condition.

• Please see Part I – Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 30, 2026, and as amended on April 30, 2026, as well as other documents we file with the SEC from time-to-time, for other important factors that could…

• We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personal…

相对上期删除的文字 · 来源:10-Q · 2025-11-12

• ● our secured lender has the right to foreclose on substantially all of our assets if we are unable to timely repay our outstanding obligations;

• ● the delisting of our Common Stock from Nasdaq has adversely affected and may continue to adversely affect our Common Stock and business and financial condition;

• ● the effect of the removal of our Common Stock on August 18, 2025 from trading on the OTCQX for failure to meet market capitalization requirements and subsequent placement on the OTCID;

• ● our ability to remediate the material weakness identified in our internal control over financial reporting as of September 30, 2025;

• ● any impacts from current global, economic, sovereign and political conditions and uncertainties, including the effects of, and uncertainty regarding, new or proposed tariff or trade regulations;

相对上期新增的文字 · 来源:10-Q · 2026-05-12

• Based on management’s evaluation of the Company’s disclosure controls and procedures, the principal executive officer and principal financial officer of the Company have concluded that the Company’s disclosure controls and procedures were effective as of March 31, 2026.

• Reference should be made to our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026, as amended, for additional information regarding discussion of the effectiveness of the Company’s controls and procedures.

相对上期删除的文字 · 来源:10-Q · 2025-11-12

• Based on management’s evaluation of the Company’s disclosure controls and procedures, the principal executive officer and principal financial officer of the Company have identified a material weakness in the Company’s internal control over financial reporting in the quarterly period ended December 3…

• The Company has adopted a remediation plan, pursuant to which the Company is amending its internal controls to mitigate the material weakness which was identified by management, including holding quarterly meetings between the accounting department and lab management to discuss any agreements that m…